Promising
DHODH inhibition (pyrimidine synthesis): reduce relapses and new lesions in MS (type not specified)
MS (type not specified) · DHODH inhibition (pyrimidine synthesis)
A controlled phase 2 trial was positive. Phase 2 trials are small and often measure early markers, so this is a signal, not proof.
- Trials
- 2
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 179
Deciding trials (phase 2): 1 met, 0 did not.
Other linked trials: 1
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
- Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapsesdecides the statusMet main goal
Phase 2 · 2001 · Placebo-controlled · MSFT-NCT01487096
The median number of combined unique active lesions per scan was 0.5, 0.2, and 0.3 in the placebo, teriflunomide 7 mg/day (p < 0.03 vs placebo), and teriflunomide 14 mg/day (p < 0.01 vs placebo) groups during the 36-week double-blind treatment phase.
Read by software from the paper's abstract
Other linked trials: 1
These linked trials do not set the status.
- Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple SclerosisMain goal was not benefit (e.g. safety)
Phase 2 · 2007 · Placebo-controlled
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Status changed from Results pending to Promising
- 2026-10-27First listed as Results pending
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error